CalciMedica, Inc.
2.9700-0.10 (-3.1%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · CALC · USD
Key Stats
Market Cap
41.50MP/E (TTM)
-Basic EPS (TTM)
-1.61Dividend Yield
0%Recent Filings
8-K
Q2 loss widens; trials progress
CalciMedica reported a Q2 2025 net loss of $6.0 million, up from $4.0 million last year, with R&D expenses steady at $4.1 million amid ongoing Auxora trials. Enrollment continues in the Phase 2 KOURAGE study for AKI with respiratory failure, targeting data in early 2026, while FDA talks on a pivotal AP trial advance toward year-end alignment. Cash stands at $18.0 million, funding operations to mid-2026. Yet trial outcomes remain uncertain.
10-Q
Q2 FY2025 results
CalciMedica's Q2 FY2025 results show steady R&D spending at $4.1M, up 17% YTD to $8.3M amid Auxora's Phase 2 trials in AKI and AIPT, while G&A dipped 7% YTD to $4.8M on lower transaction costs. Operating losses widened to $6.6M from $6.5M y/y, with net loss at $6.0M versus $4.0M last year, driven by $0.3M interest expense on the new $8.5M promissory note (maturing 2028 at ~12.75%) that offset fair-value gains. Cash and short-term investments stood at $18.0M, funding operations into mid-2026, bolstered by $9.7M debt proceeds and $1.0M ATM equity. Yet clinical trial delays from enrollment hurdles remain a key risk.
8-K
Stockholders approve equity plan amendment
CalciMedica's stockholders approved an amendment to the 2023 Equity Incentive Plan at the June 24, 2025 annual meeting, boosting authorized shares by 600,000 to fuel future incentives. They also elected directors A. Rachel Leheny, Eric W. Roberts, and Frederic Guerard for three-year terms, while ratifying Baker Tilly as auditors. This bolsters talent retention amid biotech pressures.
8-K
Auditor merger prompts resignation
CalciMedica's auditor Moss Adams resigned on June 3, 2025, following its merger with Baker Tilly US, LLP, which the Audit Committee promptly approved as the new independent accounting firm. No disagreements arose on accounting matters, and Moss Adams' clean audit report for 2024 stands unmarred. This seamless switch ensures continuity. Filing confirms no prior consultations with Baker Tilly.
8-K
Q1 loss amid trial progress
CalciMedica reported a Q1 2025 net loss of $5.0 million, up from breakeven last year, driven by $4.2 million in R&D expenses tied to the ongoing Phase 2 KOURAGE trial of Auxora in AKI with respiratory failure; enrollment continues toward 150 patients, with data due end-2025. Cash stands at $24.6 million, funding operations into mid-2026, bolstered by a $10 million initial draw from a $32.5 million credit facility. A post-hoc CARDEA analysis revealed Auxora cut AKI mortality 62.7% versus placebo. Yet risks loom in trial outcomes.
ARMP
Armata Pharmaceuticals, Inc.
5.46+0.47
CLDI
Calidi Biotherapeutics, Inc.
1.49-0.03
CRMD
CorMedix Inc.
11.31+0.17
DMAC
DiaMedica Therapeutics Inc.
6.69-0.10
EDSA
Edesa Biotech, Inc.
2.07-0.09
KALA
KALA BIO, Inc.
0.80-0.03
KALV
KalVista Pharmaceuticals, Inc.
10.96-0.17
RAPT
RAPT Therapeutics, Inc.
29.78-0.35
ZURA
Zura Bio Limited
3.78+0.01
ZVSA
ZyVersa Therapeutics, Inc.
0.14-0.01